The ultimate goal of antitumor vaccines is to develop memory CD8 1 cytotoxic T lymphocytes (CTLs), which are critical mediators of antitumor immunity. We previously demonstrated that the ovalbumin (OVA)-specific CD4 1 T cell-based (OVA-T EXO ) vaccine generated using OVA-pulsed dendritic cell (DC OVA )-released exosomes (EXO OVA ) stimulate CTL responses via IL-2 and costimulatory CD80 signaling. To assess the potential involvement of other costimulatory pathways and to define the key constituent of costimulation for memory CTL development, we first immunized wild-type (WT) C57BL/6 and gene-knockout mice with WT CD4
INTRODUCTION
Vaccines that are capable of stimulating CD8 1 cytotoxic T lymphocyte (CTL) responses and memory have been extensively studied in an effort to control pathogen-induced diseases and tumor development. Stimulation of T-cell responses by antigen-presenting cells (APCs) involves at least two signaling events: one elicited by T-cell receptors (TCRs) recognizing peptide-major histocompatibility complexes (pMHC) and another triggered by costimulatory molecules (e.g., CD40, CD80, 4-1BBL and OX40L) 1 associated with the immunological synapse between the APC and the CD8 1 T cell, 2 a multiprotein signaling complex responsible for controlling T-cell activation. 1, 3 APCs also provide an additional polarization signal (signal 3), such as IL-12, 4,5 which selectively drives the development of type I or type II immunity, each characterized by a distinct microenvironment promoting a particular set of effector mechanisms. 4, 6 Following the recognition of foreign antigen (Ag), CD8
1 T cells undergo three distinct developmental phases: (i) a proliferation (primary) phase, in which naive CD8
1 T cells undergo autonomous clonal expansion and develop into effector CTLs; (ii) a contraction phase, in which approximately 95% of the effector CTLs undergo activation-induced cell death through apoptosis, allowing the remaining approximately 5%-10% of the CTLs to develop into memory CTLs; and (iii) a maintenance phase, in which memory CTLs survive for a prolonged duration. Unlike their naive counterparts, memory CTLs display enhanced responses to subsequent Ag encounters, undergoing rapid proliferation and having heightened effector functions during recall responses.
Dendritic cells (DCs) represent the most effective type of APC. DCs process exogenous Ags in their endosomal compartments, such as multivesicular endosomes, 7 which can later fuse with the plasma membrane, releasing Ag-presenting vesicles called 'exosomes'.
can be used as OVA-T EXO -cell vaccines capable of stimulating CD4
1 T cell-independent CD8 1 T-cell priming via pMHC-I-mediated targeting and via IL-2 and CD80 costimulatory signaling. 12 Additional costimulations via 4-1BBL/4-1BB, OX40L/OX40 and CD40/CD40L interactions between DCs and CD8 1 T cells have also been found to promote effector CD8 1 T-cell responses during the priming phase 13, 14 and CD8 1 Tm-cell development in the contraction phase. [15] [16] [17] [18] However, whether these costimulatory events are also involved in priming and memory development in OVA-T EXO -stimulated CD8
1
T cells is currently not well understood.
In this study, we assessed the potential role of costimulatory molecules, including CD40L, 4-1BBL and OX40L, in OVA-T EXO vaccineinduced CD8
1 CTL responses and memory development against OVA-expressing B16 melanoma in wild-type (WT) C57BL/6 mice. 2/2 mice were generated by backcrossing the designated gene KO mice onto the OTII background. All mice used in the experiments were 6-8 weeks old and were treated according to the animal care committee guidelines of the University of Saskatchewan.
MATERIALS AND METHODS

Reagents
DC and EXO preparation
The generation of bone marrow-derived mature OVA-pulsed DCs (DC OVA ) (from WT C57BL/6 mice) in the presence of GM-CSF/IL-4 (20 ng/ml) has been described previously. 11 )EXO OVA , respectively.
CD4
1 T EXO preparation
To generate active CD4 1 T cells, spleen cells from OTII mice were cultured in RPMI 1640 medium containing IL-2 (20 U/ml) and Con A (1 mg/ml) for 3 days. The Con A-activated CD4
1 T cells (ConA-T) were then purified using MACS anti-CD4 microbeads, as previously described. 19 ConA-T cells derived from OTII/CD40L In vivo cytotoxicity assay C57BL/6 mouse splenocytes were labeled with either high (3.0 mM, CFSE high ) or low (0.6 mM, CFSE low ) concentrations of CFSE. CFSE high and CFSE low cells were then pulsed with OVAI (OVA 257-264 , SIINFEKL) and irrelevant Mut1 (FEQNTAQP) peptides, which served as internal OVA-specific target cells and internal control target cells, respectively. These peptide-pulsed target cells were co-injected i.v. at a 1 : 1 ratio into mice immunized with either OVA-T EXO or OVA-T EXO harboring a specific molecular deficiency (3310 6 cells/mouse) 6 days after the immunization. Sixteen hours post-injection, the residual antigen-specific CFSE high and control CFSE low target cells remaining in the recipients' spleens were analyzed by flow cytometry. 19 Animal studies To examine antitumor protective immunity, WT C57BL/6 or CD40 2/2 mice (6/group) were injected i.v. with WT OVA-T EXO or OVA-T EXO with a specific molecular deficiency (3310 6 cells/mouse). Thirty days after the immunization, mice were challenged i.v. with Exosome-targeted CD4 1 T cell-based vaccine YF Xie et al 73 0.5310 6 OVA-expressing B16 melanoma BL6-10 OVA cells. 19 The mice were euthanized 3 weeks following tumor cell challenge, and the lung metastatic tumor colonies were counted in a blind fashion. Metastases on freshly isolated lungs appeared as discrete, black-pigmented foci in BL6-10 OVA tumors. Metastatic foci that were too numerous to count were assigned an arbitrary value of .300.
19
Statistical analysis Statistical analyses were performed using the Student's t-test or the Mann-Whitney U test 20 for comparison of variables from different groups. A value of P,0.05 or ,0.01 was considered to be statistically significant or very significant.
RESULTS AND DISCUSSION
CD4
1 OVA-T EXO cells stimulate efficient CD8 1 T-cell responses OVA-pulsed DCs (DC OVA expressed CD11c (a marker of DCs), the costimulatory molecules CD80, 4-1BBL, and OX40L and pMHC-I complexes, whereas DC OVA -released EXO (EXO OVA ) displayed these molecules to a much lesser extent (Figure 1a) . OVA-T EXO cells derived from ConA-stimulated OTII CD4
1 T lymphocytes (ConA-T) that had internalized EXO OVA expressed 4-1BBL, OX40L and CD40L ( Figure 1b) b /OVA 257-264 tetramer staining, followed by flow cytometry on day 6 post-immunization. We found that OVA-T EXO immunization induced an OVAspecific CD8
1 T-cell response (2.30% of the total CD8 1 T-cell population) in vivo that was more efficient than the DC OVA -stimulated CTL response (1.95% of the total CD8
1 T-cell population) (Figure 2a) .
CD40L, 4-1BBL and OX40L signaling are dispensable for priming effector CD8 1 
CTL responses
We previously demonstrated that CD80 costimulation plays an important role in OVA-T EXO -initiated priming of CD8 1 T-cell responses. 12 To assess the potential role of other costimulatory molecules, such as CD40L, 4-1BBL and OX40L, we immunized C57BL/6 mice with (CD40L 
CD8
1 T-cell priming. This result was further confirmed by analyzing CTL priming in WT B6 and gene KO mice that had been immunized with WT CD4
1 OVA-T EXO cells. Consistent with our earlier findings, there was also no significant difference between the WT B6 and gene KO groups (P.0.05) (Figure 2b) . To assess the effector function of primed CD8
1 T cells, we next performed an in vivo cytotoxicity assay. In this assay, OVAI peptide-pulsed/CFSE high and irrelevant Mut1 peptide-pulsed/CFSE low C57BL/6 mouse splenocytes (which served as OVA-specific and control target cells, respectively) were co-injected i.v. at a 1 : 1 ratio into C57BL/6 mice that had been immunized with WT OVA-T EXO or OVA-T EXO carrying various molecular deficiencies six days after the immunization. Sixteen hours post-injection, the residual OVA-specific CFSE high and control CFSE low target cells remaining in the recipients' spleens were analyzed by flow cytometry. We found that 88% of the OVA-specific CFSE high target cells, but none of the irrelevant control Mut1 peptide-pulsed (CFSE low ) target cells, were killed in the 16 h following the transfer of the target cells into WT OVA-T EXO -immunized mice (Figure 2c) CD40L-, but not 4-1BBL-or OX40L-induced signaling, is required for functional CTL memory development To assess whether CD8 1 memory CTLs are functional, the mice were further boosted with DC OVA 30 days after the immunization, at a timepoint when the OVA-T EXO -stimulated effector CD8
1 CTLs would have developed into memory T cells. We observed a 20-fold increase in boosted CD8
1 T cells 4 days after the boost of DC OVA in mice previously immunized with OVA-specific OVA-T EXO , CD8- (Figure 3a) . Interestingly, there was no increase in boosted CD8
1 T cells in mice previously immunized with (CD40L 2/2 )T EXO (P,0.05) (Figure 3a ), suggesting that CD40L-, but not 4-1BBL-or OX40L-signaling by CD4
1 T EXO cells is required for functional CD8 1 T-cell memory development. This observation was further confirmed by our finding that CD40
2/2 CTLs also had defects in their recall responses in CD40 2/2 mice that had previously been primed by WT OVA-T EXO (Figure 3b) . To assess the antitumor immunity in these mice, we further challenged the immunized mice with the OVA-expressing B16 melanoma cell line BL6-10 OVA 30 days after the primary immunization. We found that all OVA-T EXO -immunized mice were significantly more protected against BL6-10 OVA tumor challenge compared to (CD40L 2/2 )T EXOimmunized mice (P,0.01) (Figure 3c ), confirming the loss of functional CTL memory derived from (CD40L 24 Unfortunately, these attempts have demonstrated only limited efficacy, mainly due to the silencing effect imposed on DCs by the tumor-tolerogenic microenvironment. 25 In addition, similar to many other types of vaccines, such as DNA, tumor lysates, tumor antigens or peptides, DC vaccines rely on CD4 1 T cell-dependent CTL responses and antitumor immunity. In clinical practice, a wealth of data indicate that antitumor immunity directed against a wide variety of malignancies is suppressed in cancer patients. 26 Suppressive CD4 1 T cells, including Tr1, Th2 and natural CD4 1 25 1 Tr cells, play a critical role in the mediation of the suppression. 27, 28 In cancer patients, enrichment of CD4 1 25 1 Tr cell populations has been observed both in the circulation and in the tumor microenvironment. 29, 30 We previously showed that (i) the novel EXO-targeted OVA-T EXO cells were able to directly stimulate CTL responses in the absence of host CD4
1 T-cell help and trigger more efficient CTL responses compared to DC OVA ; (ii) pMHC-I, CD80 signaling and IL-2 signaling play important roles in CD4
1 OVA-T EXO -stimulated CTL responses; and (iii) OVA-T EXO cells triggered OVA-specific CTL responses in C57BL/ 6 mice, even following the transfer of CD4 1 25 1 Tr cells, by counteracting CD4 1 25 1 Tr tolerance. 12 In this study, we further demonstrate that CD4
1 T cell-based OVA-T EXO vaccination stimulates functional long-term CTL memory via CD40L signaling, indicating that (i) the three signals required for OVA-T EXO to induce a T-cell response (pMHCI/TCR, costimulatory signal such as CD80/CD28 and CD40L/ CD40, and IL-2) are distinct from the three signals required for DCs (pMHCI/TCR, CD80/CD28 and IL-12); 4, 5 and (ii) CD40L signaling plays an important role in OVA-T EXO -stimulated functional memory CTL development.
Overall, this work suggests that a novel CD4 1 T cell-based vaccine capable of stimulating long-term functional CTL memory via CD40L signaling may represent a novel and efficient approach to antitumor vaccination.
